|
Title
|
|
|
|
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)
| |
|
Author
|
|
|
|
| |
|
Institution/Organisation
|
|
|
|
EORTC Gynaecological Canc Grp
| |
|
Abstract
|
|
|
|
| Purpose: The study was designed to determine independent prognostic variables in suboptimally debulked advanced ovarian cancer patients entered in the randomised phase III study EORTC S5865. Experimental design: Retrospectively collected paraffin blocks from 169 patients with stages IIb-IV epithelial ovarian cancer, taken at primary debulking surgery, were analysed. All patients were treated with cyclophosphamide and cisplatin (CP), and followed up for a median of 10 years. Expression of p53, bcl-2, P21, Ki-67 and HER-2 status was assessed by immunohistochemistry (IHC). Results: Expression of p21, a downstream effector of the p53 gene, was found to be a favourable prognostic factor for survival (HR 0.58, Cl 0.36-0.94, p = 0.025) in addition to FIGO stage (HR 1.54, Cl 1.08-2.21, p = < 0.02). For progression free survival (PFS), both p21 (HR 0.52) and Ki-67 (HR 0.6) were significant factors. Conclusion: P21 overexpression is a positive prognostic factor for survival and PFS in advanced ovarian carcinoma with residual lesions of more than 1 cm. (c) 2006 Elsevier Ltd. All rights reserved. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
European journal of cancer. - Oxford, 1965 - 1981
European journal of cancer. - Oxford, 1990, currens
| |
|
Publication
|
|
|
|
Oxford
:
2006
| |
|
ISSN
|
|
|
|
0014-2964
[print]
1879-2995
[online]
| |
|
Volume/pages
|
|
|
|
42
:15
(2006)
, p. 2539-2548
| |
|
ISI
|
|
|
|
000241926300026
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|